Covered recipient · General Payments record
SUZANN SZEWCZAK
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$3,609.56
- Reported across 238 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $329.63 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $96.03 | 5 |
| Novo Nordisk AS | $84.28 | 5 |
| PFIZER INC. | $59.40 | 3 |
| Amgen Inc. | $34.09 | 2 |
| Phathom Pharmaceuticals, Inc. | $23.74 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $16.20 | 1 |
| Lundbeck LLC | $15.89 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $20.58 | 01/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106192750 | CMS |
| ABBVIE INC. | $17.43 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106192752 | CMS |
| ABBVIE INC. | $20.87 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106192754 | CMS |
| ABBVIE INC. | $20.81 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106192756 | CMS |
| ABBVIE INC. | $16.34 | 11/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106192758 | CMS |
| Amgen Inc. | $16.35 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116166332 | CMS |
| Amgen Inc. | $17.74 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117696796 | CMS |
| Lundbeck LLC | $15.89 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145973780 | CMS |
| Novartis Pharmaceuticals Corporation | $16.20 | 05/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087345045 | CMS |
| Novo Nordisk Inc | $14.43 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096835110 | CMS |
| Novo Nordisk Inc | $14.58 | 02/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096890272 | CMS |
| Novo Nordisk Inc | $15.41 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097628214 | CMS |
| Novo Nordisk Inc | $20.24 | 04/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096680690 | CMS |
| Novo Nordisk Inc | $19.62 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097763528 | CMS |
| PFIZER INC. | $17.83 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131139382 | CMS |
| PFIZER INC. | $19.65 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131346664 | CMS |
| PFIZER INC. | $21.92 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132120489 | CMS |
| Phathom Pharmaceuticals, Inc. | $23.74 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151131551 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.